In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates
ConclusionSynergistic and additive effects between these two-drug combinations offer an attractive chemotherapeutic regimen against drug-resistant clinical MTB isolates.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
More News: Antimicrobial Resistance | Avelox | Bedaquiline | Infectious Diseases | Moxifloxacin | Study | Tuberculosis